A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection therapy between 2012 and 2022 in our institution...
Main Authors: | Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso, Dennis A. Hesselink |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Transplant International |
Subjects: | |
Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2023.11834/full |
Similar Items
-
Virus-specific TRM cells of both donor and recipient origin reside in human kidney transplants
by: Daphne M. Hullegie-Peelen, et al.
Published: (2023-11-01) -
Corrigendum: The mast cell: A Janus in kidney transplants
by: G. van der Elst, et al.
Published: (2023-03-01) -
The mast cell: A Janus in kidney transplants
by: G. van der Elst, et al.
Published: (2023-02-01) -
Causes of Kidney Graft Failure in a Cohort of Recipients With a Very Long-Time Follow-Up After Transplantation
by: Michiel G. H. Betjes, et al.
Published: (2022-06-01) -
Pre-transplant kidney quality evaluation using photoacoustic imaging during normothermic machine perfusion
by: Anton V. Nikolaev, et al.
Published: (2024-04-01)